Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

UTL-5g is a chemo- and radioprotective agent.1,2,3 It reduces LPS-induced transcriptional activity mediated by a variety of immune-related transcription factors, including STAT1, STAT2, STAT3, and SMAD2-4 but not NF-κB in RAW 264.7 macrophages.2 It also reduces hyperphosphorylation of proteins involved in the G2/M phase transition, phagocytosis, and actin remodeling. It reduces radiation-induced increases in liver TNF-α levels in mice when administered at doses of 30 and 60 mg/kg and is protective against liver radiation-induced hepatotoxicity in mice at 60 mg/kg.1 Oral administration of UTL-5g (60 mg/kg) increases the survival rate in a mouse model of acute cisplatin (Item No. 13119) toxicity.3
WARNING This product is not for human or veterinary use.
1. Pretreatment with a small-
2. Phosphoproteome and transcription factor activity profiling identify actions of the anti-
3. The small-